Unknown

Dataset Information

0

LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.


ABSTRACT: The leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is the most common genetic determinant of Parkinson disease (PD) identified to date. It accounts for 1%-7% of PD in patients of European origin and 20%-40% in Ashkenazi Jews and North African Arabs with PD. Previous studies concluded that patients from these populations all shared a common Middle Eastern founder who lived in the 13th century. We tested this hypothesis by genotyping 25 microsatellite and single-nucleotide-polymorphism markers in 22 families with G2019S and observed two distinct haplotypes. Haplotype 1 was present in 19 families of Ashkenazi Jewish and European ancestry, whereas haplotype 2 occurred in three European American families. Using a maximum-likelihood method, we estimated that the families with haplotype 1 shared a common ancestor 2,250 (95% confidence interval 1,650-3,120) years ago, whereas those with haplotype 2 appeared to share a more recent founder. Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas.

SUBMITTER: Zabetian CP 

PROVIDER: S-EPMC1592578 | biostudies-literature | 2006 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.

Zabetian Cyrus P CP   Hutter Carolyn M CM   Yearout Dora D   Lopez Alexis N AN   Factor Stewart A SA   Griffith Alida A   Leis Berta C BC   Bird Thomas D TD   Nutt John G JG   Higgins Donald S DS   Roberts John W JW   Kay Denise M DM   Edwards Karen L KL   Samii Ali A   Payami Haydeh H  

American journal of human genetics 20060817 4


The leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is the most common genetic determinant of Parkinson disease (PD) identified to date. It accounts for 1%-7% of PD in patients of European origin and 20%-40% in Ashkenazi Jews and North African Arabs with PD. Previous studies concluded that patients from these populations all shared a common Middle Eastern founder who lived in the 13th century. We tested this hypothesis by genotyping 25 microsatellite and single-nucleotide-polymorphism marke  ...[more]

Similar Datasets

| S-EPMC3859844 | biostudies-literature
| S-EPMC8060834 | biostudies-literature
| S-EPMC7477385 | biostudies-literature
| S-EPMC4799717 | biostudies-literature
2019-10-31 | GSE139579 | GEO
| S-EPMC8638676 | biostudies-literature
| S-EPMC3430708 | biostudies-literature